Core Insights - Conestoga Capital Advisors reported that US equities had solid returns in 2025, with double-digit gains across major indices, but underlying conditions showed extreme volatility and market leadership [1] - The Small Cap Strategy of Conestoga Capital Advisors returned -1.89% net-of-fees in Q4 2025, underperforming the Russell 2000 Growth Index, which returned 1.22% [1] - The rally in "low quality" stocks continued in Q4 2025, albeit at a slower pace compared to previous quarters [1] Company-Specific Insights - Mesa Laboratories, Inc. (NASDAQ:MLAB) is a provider of life sciences tools and quality control products, with a one-month return of 11.32% but a 52-week loss of 35.06% [2] - As of February 19, 2026, Mesa Laboratories, Inc. had a stock price of $92.02 and a market capitalization of $508.393 million [2] - Conestoga Capital Advisors expressed concerns about Mesa Laboratories' long-term growth prospects, citing pressures from end-market weakness, particularly in cell and gene therapy and in China [3] - The company exited its position in Mesa Laboratories due to insufficient conviction in its growth potential and limited organic growth opportunities [3] - Mesa Laboratories was not among the 30 most popular stocks among hedge funds, with 20 hedge fund portfolios holding the stock at the end of Q3 2025, an increase from 12 in the previous quarter [5] - Conestoga Capital Advisors believes that certain AI stocks present greater upside potential and less downside risk compared to Mesa Laboratories [5]

Core Insights - Baron Health Care Fund reported a 13.10% increase in the fourth quarter, outperforming the Russell 3000 Health Care Index's 11.92% and the Russell 3000 Index's 2.40% [1] - For the full year, the Fund returned 10.28%, while the benchmarks gained 14.56% and 17.15% respectively [1] - The Fund focuses on investing in businesses with sustainable competitive advantages and strong management, particularly in the healthcare sector, which is expected to show positive momentum through 2026 [1] Company Specifics - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as a key stock in the Fund's fourth-quarter letter, with a one-month return of -12.36% and a 52-week loss of 5.09% [2] - As of February 5, 2026, Thermo Fisher's stock closed at $542.36, with a market capitalization of $203.769 billion [2] - The Fund has increased its position in Thermo Fisher, citing improving end markets for life sciences tools and stable biopharmaceutical R&D investment [3] - Management of Thermo Fisher anticipates organic revenue growth of 3% to 6% for 2026 and 2027, with potential for mid-to-high single-digit adjusted operating income growth [3] - Long-term growth drivers in the life sciences tools industry are expected to enable Thermo Fisher to achieve over 7% organic revenue growth beyond 2027 [3]

Company Overview - Tecan Company is participating in the 44th JPMorgan Healthcare Conference, with a presentation led by CEO Monica Manotas [1] - The presentation is structured to last for 30 minutes, followed by a 10-minute Q&A session [1] Leadership Background - Monica Manotas has been with Tecan for approximately 5 months and has over 25 years of experience in the life sciences tool industry [2] - Prior to her current role, she had significant interactions with Tecan while at Thermo Fisher, which provided her familiarity with Tecan's product portfolio and the team behind it [3] - Manotas joined the Board of Tecan in 2024, indicating a long-standing interest and connection with the company [3]

Group 1: Procter & Gamble (PG) - Procter & Gamble is highlighted as a favorite tech stock by Cramer, who emphasizes its significant investment in innovation, spending over $2 billion annually on new product development [2] - The company, known for brands like Pampers and Gillette, has seen a nearly 13% decline year-to-date, which Cramer attributes to a de-risking rather than a fundamental issue [2] - Cramer notes that Procter & Gamble has successfully utilized artificial intelligence to enhance its supply chain, leading to substantial cost savings and faster product market introduction [4] Group 2: Danaher (DHR) - Danaher is identified as one of the "out-of-favor stocks to buy," with Cramer suggesting it is poised for recovery after a period of negative performance [4][5] - The company, which provides tools and technologies to the healthcare sector, has experienced a recovery over the past six months, gaining more than 12% [5] - Wells Fargo has raised its price target for Danaher from $230 to $240, anticipating increased organic growth in the life sciences tools industry next year [5]

Core Insights - Tempus AI (TEM) experienced a significant quarter with improved diagnostics volumes and pricing, alongside extended data partnerships enhancing visibility [1] - Investors are evaluating growth sustainability against GAAP losses and the timing of multi-year data deal conversions [1] Revenue Growth and Performance - In Q3 2025, revenues surged 84.7% year-over-year to $334.2 million, driven by a 117% increase in genomics to $252.9 million and a 26.1% rise in data and services to $81.3 million [2] - The company conducted 217,000 clinical tests, marking a 33% year-over-year increase, with oncology testing revenue at $139.5 million and hereditary testing at $102.6 million [2] Margin and Profitability Trends - Gross profit increased by 98% to $209.9 million due to higher volumes and improved average selling prices [3] - Adjusted EBITDA reached $1.5 million, a notable improvement from the previous year's loss, although GAAP net loss was substantial at $80.0 million [3] Pricing and Regulatory Developments - Average reimbursement improved by mid-teens percentage per test, narrowing the gap with competitors [4] - Approximately one-third of xT CDx volume is on FDA-approved pathways, with plans to migrate most by 2026, and xF submission for FDA approval expected by the end of 2025 [4] Data Monetization and Future Visibility - Data and services are showing momentum in multi-quarter bookings, which are expected to convert over time, enhancing operating leverage [5] - The company is building a backlog through Compass CRO awards and real-world data collaborations, although the conversion cycle may limit near-term revenue growth [5] Financial Position and Guidance - Tempus AI ended Q3 with $764.3 million in cash and marketable securities, providing sufficient capacity for AI compute, regulatory filings, and commercial investments [6] - For 2025, management anticipates approximately $1.265 billion in revenue and around $20 million in adjusted EBITDA, with a target for positive annual earnings per share by 2027 [6]

Group 1 - Wolfe Research upgraded Waters Corporation (WAT) to Outperform from Peer Perform [2] - The upgrade is based on potential tailwinds from Waters' proposed merger with Becton, Dickinson (BDX) Biosciences & Diagnostic Solutions unit [2] - The merger is expected to enhance Waters' market position and growth prospects in the life sciences tools sector [2]

Group 1 - Harding Loevner's Global Equity Strategy reported a gross return of 2.62% and a net return of 2.52% for Q3 2025, underperforming the MSCI All Country World Index and MSCI World Index, which returned 7.74% and 7.36% respectively [1] - Year-to-date, the strategy has risen 10.61% net, compared to 18.86% and 17.83% for the respective indexes [1] - The last six months have been characterized as one of the strongest momentum phases in over 70 years, with high-momentum stocks outperforming low-momentum stocks by 45 percentage points, largely driven by advancements in AI [1] Group 2 - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as a key stock, with a one-month return of 2.56% and a 52-week gain of 11.44% [2] - As of December 3, 2025, Thermo Fisher's stock closed at $580.45 per share, with a market capitalization of $218.08 billion [2] Group 3 - The investor letter indicated that the Health Care sector is showing signs of recovery despite previous sales declines attributed to pandemic-inflated levels [3] - Operating fundamentals in key end markets are stabilizing, with improved hospital finances in early 2025 as volumes normalized and revenue growth outpaced expenses [3] - Medical technology and services companies are expected to gain better pricing power and a favorable sales mix if patient utilization stabilizes, while life sciences tools may benefit from improved capital budgets [3] - Thermo Fisher's management forecasted 3-6% organic revenue growth for the next year and 7% beyond 2027, which was better than investor expectations, leading to a positive stock performance [3]

Core Insights - 10x Genomics has launched its next-generation Chromium Flex assay, which significantly enhances the capacity for single-cell experiments by supporting up to 384 samples and processing as many as 100 million cells per week [1][2]. Group 1: Product Launch and Features - The new Chromium Flex assay is designed for high cell-number applications like CRISPR screens and high sample-number applications such as FFPE-based translational research [2]. - This release allows laboratories to achieve throughput levels previously only possible with bulk methods while maintaining single-cell resolution, marking a "transformational step forward" for foundational and translational research according to CTO Michael Schnall-Levin [2]. Group 2: Market Target and Applications - The Chromium Flex assay is now globally available and targets academic, biotech, and pharmaceutical labs that require automated, high-throughput solutions for precision cell profiling [3]. - 10x Genomics specializes in life sciences tools, developing platforms for single-cell and spatial biology, enabling high-resolution molecular analysis across various research domains including oncology, immunology, and neuroscience [3].

Core Viewpoint - Baron Health Care Fund's performance in Q3 2025 was a 5.39% increase, slightly outperforming the Russell 3000 Health Care Index's 5.05% gain, but lagging behind the broader Russell 3000 Index's 8.18% increase, primarily due to stock selection offset by negative impacts from sub-industry allocations and cash holdings during a rising market [1] Group 1: Fund Performance - The Baron Health Care Fund rose 5.39% in Q3 2025 compared to a 5.05% gain for its benchmark [1] - The fund's performance was similar to the benchmark, with solid stock selection being offset by negative effects from active sub-industry allocations and cash holdings [1] Group 2: Thermo Fisher Scientific Inc. (NYSE:TMO) - Thermo Fisher Scientific Inc. is highlighted as a key stock in the fund's portfolio, with a one-month return of 4.31% and a 52-week gain of 2.15% [2] - As of October 31, 2025, Thermo Fisher's stock closed at $567.39, with a market capitalization of $214.253 billion [2] - The fund added to its position in Thermo Fisher, which is expected to achieve 3% to 6% organic revenue growth in 2026 and 2027, with potential for mid-to-high single-digit adjusted operating income growth [3] - Management anticipates that beyond 2027, Thermo Fisher could deliver over 7% organic revenue growth due to positive long-term drivers in the life sciences tools industry [3] - Thermo Fisher Scientific's revenue grew 3% to $10.85 billion in Q2 2025, and it ranks 26th among the 30 most popular stocks among hedge funds, with 117 hedge fund portfolios holding its shares [4]

Market Overview - U.S. stocks maintained momentum in Q3, with S&P 500 and Nasdaq reaching new records due to improved confidence from tariffs, legislative actions, and a Federal Reserve rate cut [3] - Strong earnings from major companies in communication services, information technology, and consumer discretionary sectors contributed to the market rally [3] Sector Performance - Information Technology sector outperformed, particularly semiconductor companies like Broadcom, Intel, and Taiwan Semiconductor, driven by increased spending on artificial intelligence [4] - Health care stocks faced regulatory pressures, but companies like UnitedHealth and Thermo Fisher Scientific showed resilience, offsetting weaknesses in others like Novo Nordisk [5] - Utilities sector, led by Sempra, saw double-digit gains as it regained investor confidence and strengthened its financial position [6] - Communication services faced challenges, with Alphabet performing well but Comcast struggling with market share losses [7] - Financials experienced slight underperformance, with a shift from U.S. Bancorp to PNC due to better execution confidence [8] - Materials sector faced demand softness, particularly in China and Europe, impacting companies like Air Products and Deere [9] Portfolio Positioning - The strategy has been adjusted to address underperformance, focusing on high-quality companies and reducing exposure to high-volatility stocks [10][11] - A tighter risk framework has been implemented, monitoring key performance indicators to enhance decision-making [11] Outlook - The market outlook remains cautiously optimistic, emphasizing high-quality companies with durable business models amid rising inflation and interest rates [13] - The investment landscape is shifting, with opportunities in overlooked, high-quality businesses as capital flows away from high-growth stocks [13] Portfolio Highlights - The ClearBridge Large Cap Value Strategy outperformed its benchmark, with positive contributions from IT, health care, and utilities sectors [14] - Stock selection and sector allocation were key drivers of outperformance, particularly in IT and health care [15] - Top contributors included Sempra, Broadcom, and Taiwan Semiconductor, while detractors included Deere and Novo Nordisk [16]